Expert RA upgraded PROMOMED DM's credit rating to ruA
13.12.2024
13.12.2024
December 13, Moscow.
MedicationEnligria®, developed by PROMOMED Group of companies, entered the TOP 3 in the category "Best Local Brand in Russia in 2024" at the IQVIA Awards. This achievement highlights the importance and quality of the product in the Russian pharmaceutical market.
Enligria® became the first domestic drug of the glutide group (glucagon-like peptide-1 receptor agonists) intended for the treatment of patients with type 2 diabetes mellitus, overweight and obesity. In addition, the drug helps in the prevention of cardiovascular complications associated with these diseases.
The creation of domestic drugs for the treatment of obesity has been a priority for PROMOMED for many years. The company's endocrinology portfolio also includes well-proven drugs.Quincenta® andVelgia®, which are aimed at reducing body weight and restoring metabolic health. This minimizes the serious complications of obesity, such as cardiovascular disasters, the development of type 2 diabetes, decreased fertility, and disorders of the musculoskeletal system.
New drugs expand the toolkit for doctors, making effective therapy and prevention of socially significant diseases accessible and personalized for every patient in Russia, regardless of gender, age, and the presence of concomitant diseases.
Winning the IQVIA Awards is a sign of product quality and recognition of its relevance. This award is an excellent motivation for the PROMOMED team to develop and reach new heights.
Stay informed
Stay informed
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office